Latest Revenue Growth News

Botanix Pharmaceuticals reported a robust 28% increase in net revenue for Sofdra in Q2 FY26, driven by a 24% rise in prescriptions and a growing US sales team. The company maintains a strong cash position while navigating higher operating costs.

A small-cap healthcare rally had a clear centre: distribution deals, US regulatory steps, and big cheques. Osteopore, Echo IQ and Anteris led the week, while a handful of names slipped despite solid operational updates.

A wild week for small-cap tech, led by a price-query rocket in DTI and a heavy sell-off in Qoria despite strong recurring revenue growth. Cash receipts, contract wins and capital raises did most of the talking, while a few gap moves showed how fast early gains can vanish.

A control fight and a big private equity payout topped this week’s finance moves, while several small-cap lenders and fund managers slid hard. Platform operators kept printing inflows, but investors stayed quick to punish anything that looked uncertain.

A takeover offer lit up small caps, while one high-growth software name slid hard despite strong sector news. Resources dominated the winners list, but investors still punished dilution and discounted fundraisings.

DroneShield Limited has triggered the vesting of over 9 million performance options following a significant $200 million cash receipts milestone, reflecting rapid growth and a new incentive framework.

ReadCloud Limited has secured over 50 new school contracts for 2026, driving strong growth in its VET-in-Schools and eBooks divisions despite ongoing funding challenges in its Industry Training segment.

Visionflex Group Limited reported a mixed quarter with a modest cash burn but strengthened its balance sheet through a significant debt-to-equity conversion and maintained solid funding capacity.

Mayfield Group Holdings has acquired a strategic industrial property adjacent to its BE Switchcraft operations, enabling operational synergies and capacity expansion to support a $30 million contract pipeline.

Visionflex Group’s Q2 FY26 report reveals a 23% rise in annual recurring revenue and improved cash flow, even as overall revenue slips due to lower hardware sales.

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.

Korvest has reported a solid first half for FY26 with revenue up 17.9% and EBIT rising 36.3%, underpinned by major project wins and operational upgrades. The Kilburn redevelopment is progressing on schedule, setting the stage for further growth.